EUVIMEDEUVIMED entdecken
Studienprotokoll

Preoperative short‐course radiotherapy followed by chemotherapy and PD‐1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study)

Wenjue Zhang iD, Yuan Tang, Lichun Wei, Shixin Liu, Wenling Wang, Yihebali Chi, Ying Wang, Wenyan Kang, Wenting Huang, Feiyan Deng, Haoyue Li, Huiying Ma iD und 8 weitere

Colorectal Disease · 2024

DOI: 10.1111/codi.17090 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Colorectal Disease, 2024. Verfasst von Wenjue Zhang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center/National Clinical Research Centre for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Ac…. Hauptthemen laut MEDLINE: Clinical Trials, Phase II as Topic, Immune Checkpoint Inhibitors, Neoadjuvant Therapy, Rectal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

For patients with locally advanced rectal cancer, previous STELLAR studies have shown that a new adjuvant treatment paradigm of short‐course radiotherapy followed by neoadjuvant chemotherapy can achieve pathological complete response rates superior to those of standard care; however, the 3‐year DFS is inferior to neoadjuvant concurrent radiotherapy. Recent studies have shown that immune checkpoint inhibitors may improve the prognosis of rectal cancer and have good synergy with radiotherapy. Therefore, neoadjuvant chemotherapy combined with immune checkpoint inhibitors after a short course of radiotherapy has the potential to further improve complete response rates and prognosis.

Method

The STELLAR II study is a multicentre, open label, two‐arm randomized, phase II/III trial of short‐course radiotherapy followed by neoadjuvant chemotherapy concurrent with immunotherapy for locally advanced rectal cancer. A total of 588 patients with locally advanced rectal cancer (LARC) will be randomly assigned to the experimental and control groups. The experimental group will receive short‐course radiotherapy and neoadjuvant chemotherapy in combination with sindilizumab, while the control group will receive short‐course radiotherapy and neoadjuvant chemotherapy. Both groups will subsequently receive either total rectal mesenteric resection or a watch & wait (W&W) strategy. The phase II primary endpoint is the complete remission rate, and the secondary endpoints include grade 3–4 adverse events, perioperative complications, R0 resection rate, overall survival, local recurrence rate, distant metastasis rate and quality of life score. A seamless phase II/III randomized controlled design will be used to investigate the effectiveness and safety of the TNT strategy with the addition of immunotherapy. The trial opened, and the first patient was recruited on 31 August 2022. Trial registration number and date of registration: ClinicalTrials.gov NCT05484024 , 29 July 2022.

Discussion

The STELLAR II trial will prospectively evaluate the efficacy of TNT treatment strategies that incorporate immune checkpoint inhibitors. The trial will yield important information to guide routine management of patients with local advanced rectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase II as TopicImmune Checkpoint InhibitorsNeoadjuvant TherapyRectal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedClinical Trials, Phase III as TopicMulticenter Studies as TopicRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

immunotherapylocally advanced rectal cancershort‐course radiotherapytotal neoadjuvant therapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, National Cancer Center/National Clinical Research Centre for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen,…
  • State Key Laboratory of Molecular Oncology, Department of Radiation Oncology, National Cancer Center/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Med…
  • Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Department of Radiation Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
  • Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
  • State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medic…

ORCID-Profile: Wenjue Zhang, Huiying Ma

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., Tang, Y., Wei, L., Liu, S., Wang, W., Chi, Y., Wang, Y., Kang, W., Huang, W., Deng, F., Li, H., Ma, H., Jiang, L., Ding, Z., Feng, L., Li, Y., Chen, Y., Zhou, H., Hu, C., & Jin, J. (2024). Preoperative short‐course radiotherapy followed by chemotherapy and PD‐1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study). Colorectal Disease. https://doi.org/10.1111/codi.17090

Vancouver

Zhang W, Tang Y, Wei L, Liu S, Wang W, Chi Y, et al. Preoperative short‐course radiotherapy followed by chemotherapy and PD‐1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study). Colorectal Disease. 2024. doi:10.1111/codi.17090

BibTeX
@article{Zhang2024,
  author = {Zhang, Wenjue and Tang, Yuan and Wei, Lichun and Liu, Shixin and Wang, Wenling and Chi, Yihebali and Wang, Ying and Kang, Wenyan and Huang, Wenting and Deng, Feiyan and Li, Haoyue and Ma, Huiying and Jiang, LiMing and Ding, Zhen and Feng, Lingling and Li, Yexiong and Chen, Yinggang and Zhou, Haitao and Hu, Chen and Jin, Jing},
  title = {Preoperative short‐course radiotherapy followed by chemotherapy and PD‐1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study)},
  journal = {Colorectal Disease},
  year = {2024},
  doi = {10.1111/codi.17090}
}
Kostenlos starten →